Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Australasian Leukaemia and Lymphoma Group
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00053092
First received: January 27, 2003
Last updated: December 17, 2013
Last verified: June 2007